Clinical Trial Detail

NCT ID NCT02431208
Title A Study of Atezolizumab (Anti-Programmed Death Ligand 1 [PD-L1] Antibody) Administered With or Without Lenalidomide in Participants With Multiple Myeloma (MM)
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications

multiple myeloma

Therapies

Lenalidomide

Atezolizumab

Age Groups: adult

No variant requirements are available.